J&J Rx drug sales flat, consumer and devices up

Share this article:
Johnson & Johnson flaunted the benefits of its diversified and global business portfolio today, reporting respectable third-quarter results despite static worldwide pharmaceutical sales of $6.1 billion.

Overall sales were up 6.4% for the quarter, year-on-year, to $15.9 billion. But with the company's prescription drugs business hit by generic competition and overall US sales flat, the growth came from J&J's consumer products and medical device and diagnostics businesses, along with healthy international sales.

Schizophrenia drug Risperdal, in particular, lost US patent protection in June and saw sales slide 62% year-on-year. Long-acting injectable Risperdal Consta, which remains on-patent, saw a 10% jump in sales. Other strong performers among the company's portfolio of prescription drugs included Velcade for multiple myeloma; Remicade for Chron's, rheumatoid arthritis and psoriasis; and Topamax for epilepsy and migranes.

Worldwide consumer sales were up 13.1% to $4.1 billion on a successful US launch of OTC Zyrtec and strong sales of Listerine, Neutrogena, Clean & Clear and Aveeno, as well as international baby care products and Davao, the leading moisturizer in China.

Medical devices and diagnostics sales were up 8.8% for the quarter to $5.7 billion, buoyed by strong performances by J&J Diabetes Care's blood glucose monitoring and insulin delivery products; Ethicon Endo-Surgery's minimally invasive products, Vistakon's disposable contact lenses; Ortho-Clinical Diagnostics' professional products and DePuy's orthopaedic joint reconstruction, sports medicine and trauma businesses. However, Cordis sales were hit by new competition and continuing category-wide safety fears in the drug-eluting stent market.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...